Abbott Laboratories (ABT)
NYSE: ABT
· Real-Time Price · USD
133.70
-3.70 (-2.69%)
At close: Jun 26, 2025, 3:59 PM
133.67
-0.02%
Pre-market: Jun 27, 2025, 08:00 AM EDT
Abbott Laboratories Revenue Breakdown
| Period Ending | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 | Dec 31, 2015 | Dec 31, 2014 | Dec 31, 2013 | Dec 31, 2012 | Dec 31, 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Diagnostic Products Revenue | 9.34B | 9.99B | 16.58B | 15.64B | 10.8B | 7.71B | 7.5B | 5.62B | 4.81B | 4.65B | 4.72B | 4.54B | 4.29B | 4.13B |
| Diagnostic Products Revenue Growth | -6.48% | -39.77% | +6.01% | +44.78% | +40.09% | +2.91% | +33.46% | +16.68% | +3.59% | -1.59% | +3.87% | +5.89% | +4.02% | n/a |
| Established Pharmaceutical Products Revenue | 5.19B | 5.07B | 4.91B | 4.72B | 4.3B | 4.49B | 4.42B | 4.29B | 3.86B | 3.72B | 3.12B | 4.97B | 5.12B | 5.41B |
| Established Pharmaceutical Products Revenue Growth | +2.53% | +3.14% | +4.11% | +9.64% | -4.08% | +1.45% | +3.15% | +11.09% | +3.74% | +19.31% | -37.31% | -2.87% | -5.39% | n/a |
| Medical Devices Revenue | 18.99B | 16.89B | 14.69B | 14.37B | 11.79B | 12.24B | 7.23B | 6.92B | 6.9B | 6.97B | 6.95B | 6.74B | 6.47B | 6.01B |
| Medical Devices Revenue Growth | +12.43% | +14.98% | +2.23% | +21.89% | -3.69% | +69.30% | +4.39% | +0.38% | -1.09% | +0.32% | +3.16% | +4.16% | +7.74% | n/a |
| Nutritional Products Revenue | 8.41B | 8.15B | 7.46B | 8.29B | 7.65B | 7.41B | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Nutritional Products Revenue Growth | +3.18% | +9.32% | -10.07% | +8.46% | +3.21% | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Revenue by Geography
| Period Ending | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 | Dec 31, 2015 | Dec 31, 2014 | Dec 31, 2013 | Dec 31, 2012 | Dec 31, 2011 | Dec 31, 2010 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Non-Us Revenue | 14.85B | 14.08B | 14.84B | 15.52B | 1.14B | 1.07B | 1B | 841M | 766M | 784M | 707M | 1.08B | 1.74B | 22.84B | 19.97B |
| Non-Us Revenue Growth | +5.41% | -5.10% | -4.34% | +1260.96% | +6.74% | +6.27% | +19.50% | +9.79% | -2.30% | +10.89% | -34.72% | -37.76% | -92.38% | +14.34% | n/a |
| C [N] Revenue | 2.11B | 2.25B | 2.13B | 2.39B | 1.97B | 2.35B | 2.31B | 2.15B | 1.73B | 1.8B | 1.32B | 1.07B | 933M | 16.01B | 15.19B |
| C [N] Revenue Growth | -6.21% | +5.63% | -10.83% | +21.73% | -16.24% | +1.51% | +7.69% | +24.19% | -3.79% | +35.96% | +23.46% | +14.68% | -94.17% | +5.40% | n/a |
| D [E] Revenue | 2.54B | 2.35B | 2.34B | 2.57B | 2.11B | 1.75B | 1.62B | 1.37B | 1.04B | 1B | 978M | 922M | 2.44B | n/a | n/a |
| D [E] Revenue Growth | +8.27% | +0.21% | -9.02% | +22.01% | +20.39% | +8.15% | +18.52% | +30.84% | +3.98% | +2.66% | +6.07% | -62.23% | n/a | n/a | n/a |
| I [N] Revenue | 1.82B | 1.75B | 1.65B | 1.56B | 1.32B | 1.4B | 1.33B | 1.24B | 1.11B | 1.05B | 1.01B | 1.44B | 1.88B | n/a | n/a |
| I [N] Revenue Growth | +3.83% | +6.12% | +5.64% | +17.99% | -5.30% | +4.80% | +7.76% | +11.04% | +5.79% | +4.36% | -30.03% | -23.42% | n/a | n/a | n/a |
| J [P] Revenue | 1.44B | 1.51B | 1.93B | 1.7B | 1.39B | 1.44B | 1.33B | 1.25B | 924M | 895M | 968M | 960M | 10.55B | n/a | n/a |
| J [P] Revenue Growth | -4.76% | -21.69% | +13.98% | +22.29% | -3.41% | +8.22% | +5.66% | +35.82% | +3.24% | -7.54% | +0.83% | -90.90% | n/a | n/a | n/a |
| N [L] Revenue | 1.12B | 1.07B | 1.34B | 1.31B | 1.08B | 975M | 930M | 929M | 830M | 855M | 788M | 5.28B | 16.78B | n/a | n/a |
| N [L] Revenue Growth | +4.66% | -19.61% | +1.75% | +21.13% | +11.18% | +4.84% | +0.11% | +11.93% | -2.92% | +8.50% | -85.08% | -68.52% | n/a | n/a | n/a |
| C [H] Revenue | 1.75B | 1.64B | 18.14B | 16.64B | 12.58B | 11.53B | 11.21B | 5.74B | 4.99B | 4.88B | 5.17B | 792M | n/a | n/a | n/a |
| C [H] Revenue Growth | +6.65% | -90.97% | n/a | n/a | +9.07% | +2.84% | +95.35% | +15.07% | +2.23% | -5.54% | +552.27% | n/a | n/a | n/a | n/a |
| United States Revenue | 16.32B | 15.45B | n/a | n/a | 13.02B | 11.4B | 10.84B | 9.67B | 6.49B | 6.27B | 6.12B | 6.27B | n/a | n/a | n/a |
| United States Revenue Growth | +5.64% | n/a | n/a | n/a | n/a | n/a | n/a | +49.14% | +3.44% | +2.40% | -2.33% | n/a | n/a | n/a | n/a |
Operating Expense Breakdown
| Period Ending | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | Sep 30, 2016 | Jun 30, 2016 | Mar 31, 2016 | Dec 31, 2015 | Sep 30, 2015 | Jun 30, 2015 | Mar 31, 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selling, General, and Administrative Revenue | 3.06B | 2.91B | 2.9B | 2.92B | 2.94B | 2.7B | 2.6B | 2.62B | 2.62B | 2.97B | 2.73B | 2.76B | 2.79B | 3.05B | 2.77B | 2.73B | 2.78B | 2.57B | 2.3B | 2.28B | 2.55B | 2.41B | 2.44B | 2.43B | 2.48B | 2.36B | 2.38B | 2.47B | 2.54B | 2.46B | 2.1B | 2.13B | 2.42B | 1.61B | 1.63B | 1.74B | 1.7B | 1.66B | 1.67B | 1.73B | 1.74B |
| Selling, General, and Administrative Revenue Growth | +5.30% | +0.41% | -0.69% | -0.95% | +8.84% | +3.96% | -0.69% | +0.15% | -12.04% | +8.86% | -0.94% | -1.08% | -8.56% | +10.16% | +1.50% | -2.05% | +8.29% | +11.64% | +1.14% | -10.68% | +5.59% | -1.11% | +0.25% | -1.78% | +5.04% | -0.76% | -3.61% | -2.99% | +3.25% | +17.29% | -1.55% | -12.05% | +50.65% | -1.17% | -6.28% | +2.30% | +2.60% | -0.66% | -3.53% | -0.58% | n/a |
| Research and Development Revenue | 716M | 754M | 713M | 698M | 679M | 690M | 672M | 715M | 654M | 725M | 782M | 684M | 697M | 762M | 672M | 654M | 654M | 698M | 580M | 564M | 578M | 595M | 596M | 577M | 672M | 562M | 574M | 575M | 589M | 613M | 562M | 513M | 547M | 343M | 352M | 348M | 379M | 369M | 378M | 345M | 313M |
| Research and Development Revenue Growth | -5.04% | +5.75% | +2.15% | +2.80% | -1.59% | +2.68% | -6.01% | +9.33% | -9.79% | -7.29% | +14.33% | -1.87% | -8.53% | +13.39% | +2.75% | 0.00% | -6.30% | +20.34% | +2.84% | -2.42% | -2.86% | -0.17% | +3.29% | -14.14% | +19.57% | -2.09% | -0.17% | -2.38% | -3.92% | +9.07% | +9.55% | -6.22% | +59.48% | -2.56% | +1.15% | -8.18% | +2.71% | -2.38% | +9.57% | +10.22% | n/a |